MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Test of MYMD-1 as a Treatment for Delaying Aging and Expanding Healthy And Balanced Life Expectancy

MyMD Pharmaceuticals, Inc. MYMD Stock (” MyMD” or “the Company”), a scientific phase pharmaceutical firm dedicated to extending healthy lifespan, today introduced that the initial patient has been enrolled in the Business’s Stage 2 professional test of lead candidate MYMD-1, a dental immune regulator drug, as a treatment for delaying aging as well as increasing healthy and balanced life expectancy.

The primary endpoint for the Phase 2 double-blind, placebo-controlled clinical trial is to attain a decrease in the flowing levels of (TNF-α), lump death variable receptor I (TNFRI) as well as IL-6. TNF-α and IL-6 are the proteins in the body that trigger inflammation and also aid turn on the process of aging. The second steps of the test will certainly be the safety, tolerability, and also pharmacokinetics in this populace of clients.

” In a Phase 1 medical test of MYMD-1, we demonstrated the drug’s statistically considerable effectiveness in decreasing degrees of TNF-α, a key player in causing pathological aging, in the blood. The FDA has actually approved TNF-α reduction as the key endpoint for our Stage 2 research, which our team believe placements us well for an effective Phase 2 outcome,” claimed Chris Chapman, M.D., President, Supervisor and also Principal Medical Police Officer of MyMD. “The initiation of individual enrollment in this study advances our goal to reduce the aging process, protect against loss of muscle mass tissue in aging, restriction frailty, and expand healthy and balanced lifespan.”

MyMD has specified that there are no FDA-approved medicines for treating aging problems as well as extending healthy and balanced life expectancy people, a market anticipated to be a minimum of $600 billion by 20251 according to a major investment financial institution. TNF-α blockers are the most proposed drugs by revenue, a global market of roughly $40 billion annually,2 and also, according to Nature Aging journal,3 a slowdown in maturing that would certainly boost life span by one year deserves $38 trillion as well as by 10 years is worth $367 trillion.

Along with aging, MYMD-1’s unique action in managing the immune system and also treating chronic swelling is being created for the treatment of autoimmune condition, consisting of rheumatoid arthritis (RA), several sclerosis (MS), diabetic issues, as well as inflammatory bowel disease.

” We mean to begin creating protocols for a Phase 2 pilot research study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The rising prevalence of rheumatoid joint inflammation and various other autoimmune and also inflammatory illness are driving demand for TNF preventions like MYMD-1, and also our team believe our by mouth administered medication with very low toxicity would be disruptive to the $60 billion market for RA if accepted by the FDA for this indicator.”

Rheumatoid joint inflammation impacts approximately 40 million individuals worldwide.4.

Concerning MYMD-1.

Initially created for autoimmune conditions, MYMD-1’s main purpose is to reduce the aging process, prevent sarcopenia as well as frailty, and also prolong healthy and balanced life expectancy. Since it can go across the blood-brain obstacle as well as gain access to the main nerve system (CNS), MYMD-1 is also placed to be a possible therapy for brain-related disorders. Its mechanism of activity and efficacy in conditions including several sclerosis (MS) and thyroiditis have actually been examined via collaborations with numerous academic institutions. MYMD-1 is likewise revealing assurance in pre-clinical research studies as a prospective treatment for post- COVID-19 difficulties and as an anti-fibrotic and also anti-proliferation therapeutic.

MYMD-1 has revealed performance in pre-clinical studies in controling the body immune system by carrying out as a selective prevention of growth necrosis factor-alpha (TNF-α), a driver of chronic inflammation. Unlike other therapies, MYMD-1 has actually been shown in these pre-clinical research studies to uniquely block TNF-α when it becomes overactivated in autoimmune conditions and also cytokine tornados, however not block it from doing its typical task of being an initial responder to any type of regular sort of moderate infection. MYMD-1’s simplicity of oral dosing is an additional differentiator contrasted to currently offered TNF-α blockers, every one of which require delivery by injection or infusion. No authorized TNF inhibitor has ever before been dosed orally. In addition, the medication is not immunosuppressive and also has actually not been revealed to cause the major side effects typical with conventional therapies that treat swelling.

Concerning MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific phase pharmaceutical business committed to extending healthy and balanced life expectancy, is focused on developing 2 unique therapeutic systems that deal with the sources of illness instead of just addressing the symptoms. MYMD-1 is a drug system based on a professional phase tiny molecule that regulates the body immune system to manage TNF-α, which drives persistent inflammation, and also other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, boost longevity, and also deal with autoimmune diseases and also COVID-19- associated anxiety. The Firm’s second drug system, Supera-CBD, is being developed to deal with persistent pain, addiction and also epilepsy. Supera-CBD is a novel artificial by-product of cannabidiol (CBD) as well as is being created to deal with and also surpass the rapidly expanding CBD market, which includes both FDA accepted medicines and also CBD products not currently controlled as medicines. To learn more, check out www.mymd.com.